Altium Capital Management LP Astria Therapeutics, Inc. Transaction History

Altium Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.99 - $16.69 $4.11 Million - $9.8 Million	-587,468 Reduced 80.48%	142,532 $2.01 Million
Q4 2023 Feb 14, 2024	SELL	$4.42 - $8.06 $2.73 Million - $4.97 Million	-617,088 Reduced 45.81%	730,000 $5.61 Million
Q1 2023 May 15, 2023	SELL	$11.2 - $15.79 $92,780 - $130,804	-8,284 Reduced 0.61%	1,347,088 $17.9 Million
Q4 2022 Feb 14, 2023	BUY	$7.44 - $14.89 $6.77 Million - $13.6 Million	910,372 Added 204.58%	1,355,372 $20.2 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $10.34 $1.32 Million - $4.6 Million	445,000 New	445,000 $4.02 Million

107

48.6M

48K

9.3K

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $143M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.